5 Key Takeaways

• 1

  Tissue-resident NK cells from donor blood significantly slowed solid tumor growth in mice, indicating potential for off-the-shelf cell therapy.

• 2

  Researchers differentiated NK cells into a cytotoxic tissue-resident phenotype, enhancing their infiltration into solid tumors compared to conventional NK cells.

• 3

  Adoptive transfer of these NK cells reduced tumor burden in various solid tumor models, including head and neck squamous cell carcinoma and melanoma.

• 4

  Combining tissue-resident NK cells with cetuximab resulted in greater tumor growth suppression than either treatment alone.

• 5

  The approach allows for allogeneic use of NK cells, potentially creating a non-personalized, accessible cell therapy for a broader patient population.